Celltrion, Inc.

South Korea

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Dec 12, 2017
Prev close: 205,600
Dec 12, 2017
Market cap:
Market cap(USD):
Shares: 122.66M

Currency in KRW

Company profile

Market(Ticker): KRX(068270)
Health Technology
Full time employees: --

Business summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Company background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

In the news

Financial highlights

Dec 2016

  • Local currency
  • US Dollar
Revenue 670,580.96M
Gross profit 388,407.95M
Operating income 249,614.31M
Income before tax 228,752.75M
Net income 177,994.50M
EBITDA 338,289.64M
Diluted EPS 1,454
Dividends per share --
Total assets 3,117.56B
Total liabilities 914,607.61M
Total equity 2,053.63B
Operating cash flow 230,062.47M

Currency in KRW

Revenue 577.99M
Gross profit 334.77M
Operating income 215.14M
Income before tax 197.16M
Net income 153.41M
EBITDA 291.58M
Diluted EPS 1.25
Dividends per share --
Total assets 2,581.19M
Total liabilities 757.25M
Total equity 1,700.31M
Operating cash flow 198.29M

Currency in USD

Valuation measures

Dec 2016

PER 73.46
ROA 5.98%
ROE 9.49%
Operating margin 37.22%
Profit margin 26.54%

Key executive

  • Co-Chief Executive Officer & Director: Hyung-Ki Kim
  • Co-Chief Executive Officer & Director: Wu-Sung Ki
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Shin-Jae Jang
  • Vice President: Sang-Joon Lee

Share holders

  • SEO JUNG-JIN(21.8%)
  • Temasek Holdings Pte Ltd. (Investment Management)(14.2%)
  • Schroder Investment Management Ltd.(1.6%)
  • The Vanguard Group, Inc.(1.4%)
  • BlackRock Fund Advisors(1.4%)
  • OppenheimerFunds, Inc.(1.0%)
  • Norges Bank Investment Management(0.9%)
  • Celltrion Inc. Employee Stock Ownership ASSN.(0.7%)
  • BlackRock Advisors (UK) Ltd.(0.4%)
  • Celltrion, Inc.(0.4%)


  • Website:
  • Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
  • Phone: +82.32.850.5000

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.